All In Biotech

Drug Trial Radar · NCT01332968

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

Last checked: Nov 19, 2026Latest source record: Aug 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,401

Actual

Start

Jul 6, 2011

Primary completion

Feb 1, 2016

Study completion Jul 30, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom
First posted
Apr 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

  • ObinutuzumabDrug

    Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.

  • CyclophosphamideDrug

    Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

  • DoxorubicinDrug

    Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

  • VincristineDrug

    Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.

  • PrednisoneDrug

    Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.

  • BendamustineDrug

    Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.

  • RituximabDrug

    Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival in the Follicular Lymphoma Population, Investigator-AssessedTime frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)

Locations

183 sites in 18 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas

  • The Regents of the University of California; Office of Research

    Irvine, California

  • Kootenai Cancer Center

    Post Falls, Idaho

  • Illinois Cancer Care, P.C. - Galesburg

    Galesburg, Illinois

  • Siouxland Hematology/Oncology

    Sioux City, Iowa

  • University of Kansas; Medical Center & Medical pavilion

    Westwood, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Mercy Medical Research Institute

    Springfield, Missouri

  • MT Cancer Inst Fndtn; MT Can Spec

    Missoula, Montana

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Providence St. Vincent Medical Center

    Portland, Oregon

  • Northwest Medical Specialties

    Tacoma, Washington

  • Concord Repatriation General Hospital; Haematology

    Sydney, New South Wales, Australia

  • Westmead Hospital; Haematology

    Sydney, New South Wales, Australia

  • Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology

    Woolloongabba, Queensland, Australia

  • St Vincent'S Hospital; Haematology

    Fitzroy, Victoria, Australia

  • Peter MacCallum Cancer Centre; Department of Haematology

    Melbourne, Victoria, Australia

  • Austin and Repatriation Medical Centre; Cancer Services

    Melbourne, Victoria, Australia

  • Monash Medical Centre; Haematology

    Melbourne, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • UZ Gent

    Ghent, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Tom Baker Cancer Centre-Calgary

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Dr. Georges L. Dumont University Hospital Centre

    Moncton, New Brunswick, Canada

  • Ottawa General Hospital

    Ottawa, Ontario, Canada

  • North York General Hospital

    Toronto, Ontario, Canada

  • Humber River Hospital

    Toronto, Ontario, Canada

  • Toronto East General Hospital; Haematology/Oncology

    Toronto, Ontario, Canada

  • Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie

    Greenfield Park, Quebec, Canada

  • Cancer Hospital Chinese Academy of Medical Sciences.

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • General Hospital of Chinese PLA; Department of Hematology

    Beijing, China

  • the First Hospital of Jilin University

    Changchun, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Jiangsu Province Hospital

    Nanjing, China

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.